Soufflé Therapeutics
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
$135MSeries B
ParticipantPP
Polaris Partners
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
- Rounds participated in
- 5
- Confirmed lead rounds
- 0 4 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $386M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionTavo Biotherapeutics
Develops novel therapeutics for glaucoma and retinal diseases
$17MSeries A
Role not disclosedCrossbow Therapeutics
Crossbow Therapeutics develops antibody therapies for cancer.
$77MSeries B
Role not disclosedTRex Bio
Develops precision immunoregulatory medicines based on tissue Treg biology
$50MUndisclosed
Role not disclosedEpiBiologics
Develops bispecific antibodies for targeted degradation of extracellular proteins.
$107MSeries B
Role not disclosed